Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications.

摘要: We have produced two monoclonal antibodies (mAbs), 528 IgG2a and 225 IgG1, which bind to the human EGF receptor with an affinity comparable EGF, compete for binding receptor, prevent EGF-induced activation of tyrosine kinase. The mAbs inhibit proliferation a number tumor cells bearing high numbers receptors in culture nude mouse xenographs. A431 xenographs can be imaged 111In-labeled mAb. Phase I trials were initiated patients advanced squamous cell carcinoma lung, consistently expresses receptors. IgG1 was given by single intravenous infusion. Preliminary results show no toxicity from doses up 120 mg. Tumor visualization seen dose-related. However, as other imaging studies indium-labeled antibodies, significant liver bowel isotope uptake observed. Further dose escalation is ongoing assess relationship between uptake.